Wednesday, August 24, 2011 (Last Updated: 08/25/2011)
WEDNESDAY, Aug. 24 (HealthDay News) -- Treatment with olaparib offers a promising therapeutic option for patients with ovarian cancer, according to a study published online Aug. 22 in The Lancet Oncology.
Karen A. Gelmon, M.D., from the BC Cancer Agency in Canada, and colleagues evaluated the safety and tolerability of olaparib in 90 patients with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer. Between July 2008 and September 2009, patients were administered 400 mg twice daily in this phase 2, multicenter, open-label, non-randomized study that stratified patients according to the presence or absence of BRCA1 or BRCA2 mutations. The objective response rate by Response Evaluation Criteria In Solid Tumors (RECIST) was the primary endpoint. Analysis of toxic effects was carried out in all patients who received treatment, and primary efficacy analysis in patients who had measurable lesions at baseline.
The investigators found that 63 of the 64 patients with ovarian cancer had target lesions. As per RECIST, they were evaluable for objective response, as was seen in 41 and 24 percent of patients with and without mutations, respectively. In patients with breast cancer, no confirmed objective responses were reported. Fatigue, nausea, vomiting, and decreased appetite were the most common adverse events.
"Olaparib resulted in responses in patients with high-grade serous ovarian carcinoma without germline BRCA1 or BRCA2 mutations. New treatments targeting DNA repair mechanisms seem to provide new hope for treatment of ovarian cancer," the authors write.
Several of the study authors disclosed financial ties with the pharmaceutical industry, including AstraZeneca which funded the study.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.